JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sybertz, E. J.
Right arrow Articles by Baum, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sybertz, E. J.
Right arrow Articles by Baum, T.

Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927

EJ Sybertz, CS Sabin, KK Pula, GV Vliet, J Glennon, EH Gold and T Baum

Labetalol is a mixture of four isomers. Its alpha and beta adrenergic blocking properties were compared to those of the R,R-isomer, SCH 19927. In anesthetized dogs, i.v. administration of both compounds produced competitive beta and alpha blockade as judged by inhibition of the tachycardia and vasopressor responses to i.v. injections of isoproterenol and phenylpherine, respectively. SCH 19927 was 3 to 4 times as potent as beta blocker, but only one-third as potent an alpha blocker as labetalol. Therefore, the separation of beta and alpha blocking activity of SCH 19927 clearly exceeded that of labetalol. SCH 19927 also demonstrated greater beta blocking potency than labetalol after oral administration to conscious dogs or rats that were subsequently pithed. SCH 19927 did not affect, whereas labetalol slightly reduced, pressor responses to sympathetic stimulation in the pithed rat. Both drugs were relatively devoid of intrinsic beta-1 sympathomimetic activity in the ganglion-blocked dog. It is concluded that SCH 19927 is a more potent beta adrenoceptor blocker and less potent alpha blocker than labetalol. The separation of adrenergic blocker activities indicates that steric requirements for alpha and beta blockade differ in the labetalol molecule.

Volume 218, Issue 2, pp. 435-443, 08/01/1981
Copyright © 1981 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 CirculationHome page
J. McCord, H. Jneid, J. E. Hollander, J. A. de Lemos, B. Cercek, P. Hsue, W. B. Gibler, E. M. Ohman, B. Drew, G. Philippides, et al.
Management of Cocaine-Associated Chest Pain and Myocardial Infarction: A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology
Circulation, April 8, 2008; 117(14): 1897 - 1907.
[Full Text] [PDF]

Home page
 ANGIOLOGYHome page
F. Laghi Pasini, S. Pecchi, F. Guideri, V. DeFranco, P. Damiani, C. Galigani, M. Saletti, M.S. Verzuri, P. Blardi, and T. Di Perri
Hemodynamic and Hemorheologic Effects of IV Dilevalol in Hypertensive Patients
Angiology, September 1, 1991; 42(9): 703 - 710.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics.